EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world persistence of multiple sclerosis disease‐modifying therapies

Emma C Tallantyre iD, Ruth Dobson iD, Joseph L J Froud, Frederika A St John, Valerie M Anderson, Tarunya Arun, Lauren Buckley, Nikos Evangelou, Helen L Ford, Ian Galea iD, Sumi George, Orla M Gray und 17 weitere

European Journal of Neurology · 2024-07 · 31 (7)

DOI: 10.1111/ene.16289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 03.04.2024. Verfasst von Emma C Tallantyre und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world rates of persistence on disease‐modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation.

Methods

Treatment data on 4366 consecutive people with relapse‐onset multiple sclerosis (MS) were pooled from 13 UK specialist centres during 2021. Inclusion criteria were exposure to at least one MS DMT and a complete history of DMT prescribing. PwMS in blinded clinical trials were excluded. Data collected included sex, age at MS onset, age at DMT initiation, DMT treatment dates, and reasons for stopping or switching DMT. For pwMS who had received immune reconstituting therapies (cladribine/alemtuzumab), discontinuation date was defined as starting an alternative DMT. Kaplan–Meier survival analyses were used to express DMT persistence.

Results

In 6997 treatment events (1.6 per person with MS), median time spent on any single maintenance DMT was 4.3 years (95% confidence interval = 4.1–4.5 years). The commonest overall reasons for DMT discontinuation were adverse events (35.0%) and lack of efficacy (30.3%). After 10 years, 20% of people treated with alemtuzumab had received another subsequent DMT, compared to 82% of people treated with interferon or glatiramer acetate.

Conclusions

Immune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingHumansMaleFemaleAdultMiddle AgedMultiple SclerosisImmunologic FactorsDrug Monitoring

Stichwörter der Autor:innen

disease‐modifying therapymultiple sclerosispersistencetreatment

Substanzen

Immunologic Factors

Autor:innen und Institutionen

  • Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
  • Department of Neurology, University Hospital of Wales, Cardiff, UK.
  • Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
  • Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK.
  • Postgraduate Department, St Thomas' Hospital, London, UK.
  • Department of Neuroscience, University Hospitals Coventry and Warwickshire, Coventry, UK.

ORCID-Profile: Emma C Tallantyre, Ruth Dobson, Ian Galea, Thomas E Williams

Förderung

  • Wellcome Trust

Zitieren

APA

Tallantyre, E. C., Dobson, R., Froud, J. L. J., St John, F. A., Anderson, V. M., Arun, T., Buckley, L., Evangelou, N., Ford, H. L., Galea, I., George, S., Gray, O. M., Hibbert, A. M., Hu, M., Hughes, S. E., Ingram, G., Kalra, S., Lim, C. E., Mathews, J. T. M., …, & Robertson, N. P. (2024). Real‐world persistence of multiple sclerosis disease‐modifying therapies. European Journal of Neurology, 31(7). https://doi.org/10.1111/ene.16289

Vancouver

Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, et al. Real‐world persistence of multiple sclerosis disease‐modifying therapies. European Journal of Neurology. 2024;31(7). doi:10.1111/ene.16289

BibTeX
@article{Tallantyre2024,
  author = {Tallantyre, Emma C and Dobson, Ruth and Froud, Joseph L J and St John, Frederika A and Anderson, Valerie M and Arun, Tarunya and Buckley, Lauren and Evangelou, Nikos and Ford, Helen L and Galea, Ian and George, Sumi and Gray, Orla M and Hibbert, Aimee M and Hu, Mo and Hughes, Stella E and Ingram, Gillian and Kalra, Seema and Lim, Chia-Hui E and Mathews, Joela T M and McDonnell, Gavin V and Mescall, Naomi and Norris, Sam and Ramsay, Stephen J and Rice, Claire M and Russell, Melanie J and Shawe-Taylor, Marianne J and Williams, Thomas E and Harding, Katharine E and Robertson, Neil P},
  title = {Real‐world persistence of multiple sclerosis disease‐modifying therapies},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {7},
  doi = {10.1111/ene.16289}
}
Kostenlos starten →